RxDoctor Payments Data

Natassa Quinn, DO

Internal Medicine · Brandon, FLNPI 1881630796

Payments from drug & device makers

$11,679in general payments, 2019–2025

Across 631 payments — averaging $18.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$1K
  • Pfizer$1K
  • AstraZeneca$1K
  • Lilly USA, LLC$1K
  • Bayer$554
  • plus $5K from 45 others

What the payments were for

  • Food & beverage$11,57399%
  • Education$1071%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,679 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$86,740
Medicare patients
487
Services billed
1,853

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide80$85,610
JardianceEmpagliflozin64$72,301
EliquisApixaban67$68,990
RybelsusSemaglutide37$51,704
MounjaroTirzepatide36$47,104
TrulicityDulaglutide27$29,063
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$28,130
MyrbetriqMirabegron27$22,758
MovantikNaloxegol Oxalate35$14,508
Breo ElliptaFluticasone/Vilanterol22$9,463
Stiolto RespimatTiotropium Br/Olodaterol Hcl13$9,091
Tresiba Flextouch U-200Insulin Degludec16$8,612
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog22$6,650
Omeprazole217$4,557
Atorvastatin Calcium543$4,531

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,792$137,314117 claims
Boehringer IngelheimJardiance, Stiolto Respimat$210$81,39277 claims
Lilly USA, LLCMounjaro, Trulicity$1,047$76,16763 claims
PfizerEliquis$1,199$68,99067 claims
GSKTrelegy Ellipta, Breo Ellipta$346$37,59354 claims
Astellas Pharma US IncMyrbetriq$348$22,75827 claims
AbbVieSynthroid$1,442$3,77043 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Brandon

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →